Skip to content

Assessment of Postoperative Pain After Using Various Intracanal Medication in Patients With Necrotic Pulp

Assessment of Postoperative Pain After Using Silver Nanoparticles With and Without Calcium Hydroxide as an Intracanal Medication in Patients With Necrotic Pulp: (A Randomized Clinical Trial)

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03692286
Enrollment
30
Registered
2018-10-02
Start date
2019-06-01
Completion date
2020-09-18
Last updated
2020-10-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Pain

Brief summary

To assess the Postoperative Pain after using Silver Nanoparticles with and without Calcium Hydroxide as an Intracanal Medication in Patients with necrotic pulp (RCT)

Detailed description

When the treatment itself appears to initiate the onset of pain and/or swelling, the result can be very distressing to both the patient and the operator. Patients might even consider postoperative pain and flare-up as a benchmark against which the clinician's skills are measured. Prevalence of postoperative pain or flare-up is, therefore, one of the influencing factors when making a clinical decision. Better management of postoperative pain increases the patients' confidence in dentist's skills and gives positive attitude toward dental profession. In cases with necrotic pulp, the incidence of pain becomes higher, hence testing which intracanal medication is more effective in decreasing the bacteria present within the root canal and subsequently pain is crucial.

Interventions

COMBINATION_PRODUCTSilver nanoparticle/Calcium hydroxide

Intracanal Medication composed of combined silver nanoparticles with calcium hydroxide

DRUGSilver Nanoparticles in gel form

Intracanal medication composed of silver nanoparticles in gel form

Calcium hydroxide intracanal medication

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
20 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Patients who are free from any physical or mental handicapping condition with no underlying systemic disease. * Non-pregnant females * Asymptomatic necrotic mandibular single rooted teeth. * Normal occlusal contact with the opposing teeth. * Patients accepting to participate in the study.

Exclusion criteria

* Medically compromised patients: Pain levels and healing following treatment would be compromised as these patients have shown higher incidence of pain and lower healing rate. * Pregnant women: Avoid radiation exposure, anesthesia, and medication. * If analgesics or antibiotics have been administrated by the patient during the past 12 hours preoperatively might alter their pain perception * Patients reporting bruxism or clenching: Avoid further pressure on an already inflamed tooth inducing subsequent irritation and inflammation Teeth that shows: * Association with acute periapical abscess and swelling: Need special treatment steps which could involve additional visits with incision and drainage. Also, it could influence initiation and progression of postoperative pain. * Greater than grade I mobility or pocket depth greater than 5mm. Need special surgical and/or periodontal therapy. * No restorability: Hopeless tooth. * Vital teeth * Immature teeth * Radiographic evidence of external or internal root resorption. * Any criterion, not mentioned in the inclusion criteria

Design outcomes

Primary

MeasureTime frameDescription
Change in post-operative painIntra-appointment and post obturation at 4, 24, 48, 72, 96 hoursNumerical (0-10)

Secondary

MeasureTime frameDescription
Intracanal Bacterial count reduction1 weekQuantification of Colony forming units per milliliter of agar medium (CFU/mL)
Number of analgesic tablets taken by the patient after endodontic treatmentWithin 4 days after the first session and after 1 week from first treatment sessionNumber

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026